- Home
- Shop
- New Categories
- New Blog
- Contact Us
- Cart
- Login
- Register
Select the image to view it full size.
Product details
Catalog number BNC742646-100
Price for BNC742646-100
Size / count 1x 100 µL
CD73 is a membrane-bound extracellular enzyme overexpressed in several cancer types. Its expression has been linked to poor prognosis in melanoma, colorectal, gastric, triple negative breast cancer, and to a pro-metastatic phenotype in prostate cancer. Together with CD39, it plays a major role in promoting immunosuppression through the pathway degrading adenosine triphosphate (ATP) into adenosine. Within the tumor microenvironment, ATP promotes immune cell-mediated killing of cancer cells. In contrast, adenosine accumulation causes immune suppression, dysregulation of immune cell infiltrates and stimulates angiogenesis resulting in tumor spreading. CD73 is active on the last step of the degradation pathway, where it is the enzyme that actually degrades AMP into adenosine. CD73-blockade promotes anti-tumor immunity by reducing adenosine accumulation. Accordingly, anti-CD73 mAbs stimulate anti-tumor immunity and reduce tumor metastasis in Mouse tumor models, and could enhance the efficacy of treatment with anti-PD1 or anti-CTLA4 antibodies. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.
The catalog number for CD73 (Immuno-Oncology Target) (NT5E/2646), CF740 conjugate, 0.1mg/mL is BNC742646-100.
CD73 (Immuno-Oncology Target) (NT5E/2646), CF740 conjugate, 0.1mg/mL is available in the following size(s): 1x 100 µL.
CD73 (Immuno-Oncology Target) (NT5E/2646), CF740 conjugate, 0.1mg/mL is currently made to order / not held in immediate stock. Contact us for lead time.
CD73 (Immuno-Oncology Target) (NT5E/2646), CF740 conjugate, 0.1mg/mL is manufactured by Biotium.
Estimated delivery time for CD73 (Immuno-Oncology Target) (NT5E/2646), CF740 conjugate, 0.1mg/mL is approximately 15 business day(s), depending on your location.
The safety data sheet for CD73 (Immuno-Oncology Target) (NT5E/2646), CF740 conjugate, 0.1mg/mL is available here: https://cdn.gentaur.com/products/37/68dd029d061270361e1027d0/msds/bnc742646-100.pdf.
CD73 is a membrane-bound extracellular enzyme overexpressed in several cancer types. Its expression has been linked to poor prognosis in melanoma, colorectal, gastric, triple negative breast cancer, and to a pro-metastatic phenotype in prostate cancer. Together with CD39, it plays a major role in pr
Some products are subject to special import/export regulations, dangerous goods handling, or licensing requirements. Where this applies, it’s noted on the product page, and any required extra documents or fees will be confirmed with you before dispatch, never added without your consent.
Yes, contact us with details of your sample type, species, and intended application, and our specialists will confirm suitability or suggest an alternative from our supplier network if this isn’t the best fit.
Purity, typically assessed by SDS-PAGE, is listed on the datasheet under quality control data.
